Robert Frederich

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. pmc The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
    Robert Frederich
    Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ, 08543, USA
    Diabetol Metab Syndr 4:36. 2012
  2. pmc Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
    Michael E Cobble
    Canyons Medical Center, Sandy, UT, USA
    Cardiovasc Diabetol 11:6. 2012
  3. doi request reprint A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
    Robert Frederich
    Bristol Myers Squibb, Princeton, NJ 08543, USA
    Postgrad Med 122:16-27. 2010
  4. pmc Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
    Chetan S Karyekar
    Bristol Myers Squibb, Princeton, NJ, USA
    Clin Interv Aging 8:419-30. 2013
  5. pmc Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
    Nayyar Iqbal
    Bristol Myers Squibb, Route 206 and Providence Line Rd, Princeton, NJ 08543, USA
    Cardiovasc Diabetol 13:33. 2014

Collaborators

Detail Information

Publications5

  1. pmc The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
    Robert Frederich
    Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ, 08543, USA
    Diabetol Metab Syndr 4:36. 2012
    ..abstract:..
  2. pmc Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
    Michael E Cobble
    Canyons Medical Center, Sandy, UT, USA
    Cardiovasc Diabetol 11:6. 2012
    ....
  3. doi request reprint A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
    Robert Frederich
    Bristol Myers Squibb, Princeton, NJ 08543, USA
    Postgrad Med 122:16-27. 2010
    ..The objective was to assess the relative risk (RR) for cardiovascular (CV) events across all 8 randomized phase 2/3 trials evaluating saxagliptin in patients with type 2 diabetes mellitus...
  4. pmc Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
    Chetan S Karyekar
    Bristol Myers Squibb, Princeton, NJ, USA
    Clin Interv Aging 8:419-30. 2013
    ..To assess safety and efficacy of saxagliptin in older patients with type 2 diabetes mellitus (T2DM)...
  5. pmc Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
    Nayyar Iqbal
    Bristol Myers Squibb, Route 206 and Providence Line Rd, Princeton, NJ 08543, USA
    Cardiovasc Diabetol 13:33. 2014
    ..It is important to establish the cardiovascular (CV) safety profile of novel antidiabetic drugs...